Becton, Dickinson and Company (BDX) Earnings Call Transcripts

Becton, Dickinson and Company's Latest Earnings Call - May 12, 2026

In the Q2 2026 earnings call for Becton, Dickinson and Company (BDX), management reported revenue of $4.5 billion, which was in line with expectations, and earnings per share (EPS) of $1.25, slightly missing the consensus estimate of $1.30. The company maintained its full-year guidance for low single-digit revenue growth, citing headwinds from Alaris, vaccines, and challenges in the Chinese market. However, management expressed confidence in the underlying business performance and highlighted strong growth in its Connected Care and Biopharma Solutions segments as potential catalysts for future performance.

Reported metrics

Guidance from management

Management maintained its full-year guidance for low single-digit revenue growth, indicating confidence in the underlying business despite headwinds from Alaris and vaccines.

What management said

That's more when the pharma company will start looking at placing their orders for next year. And so again, I think as Vitor mentioned, we don't expect and we have no signs as we're watching that there will be anywhere near another decrease like we saw this year as that reset. What the exact level is, we can't. it's too early to say that. But certainly, we don't expect a repeat of this year.

Yes. And again, I think this year, we have been talking about the 25% despite the tariff impact. So we've been able to kind of deliver that. So excluding the tariff, we actually had an underlying expansion of our margins. We are monitoring the inflation, which is going to be the next topic heading into. But I think we have, as Tom said, the BD excellence and the commercial execution will be the key drivers for us goi...

What analysts pressed on

Analysts expressed concerns regarding the ongoing challenges with Alaris and the impact of the vaccine revenue decline on overall growth. There were also questions about the visibility and potential recovery in the Chinese market, which remains uncertain.

Main topics on the call

• New CFO Strategy — Vitor Roque, the newly appointed CFO, emphasized a focus on capital allocation and transparency, stating, "We have been very clear on our priorities... focusing on share buybacks, maximizing shareholder return." This sig...
• Portfolio Restructuring — Management highlighted the successful restructuring of BD's portfolio, with MedTech now representing $19 billion, up from $4.5 billion a decade ago. Tom Polen noted, "The clarity of our portfolio strategy is exemplified ...
• Growth in Key Segments — The Connected Care business saw double-digit growth, with Polen stating, "Advanced patient monitoring... continues to have great momentum on the innovation side." This suggests strong demand for BD's innovative solutions...
• Challenges from Alaris and Vaccines — Management acknowledged ongoing challenges with Alaris and vaccine sales, with Roque indicating a "25% reduction this year" in vaccine-related revenue. This headwind could impact overall growth in the near term.

Read the full Becton, Dickinson and Company transcript (May 12, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 81 Becton, Dickinson and Company earnings call transcripts on record, spanning January 14, 2020 to May 12, 2026. Based on this history, Becton, Dickinson and Company reports quarterly. The most recent call on file is dated May 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BDX

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

81

First call

January 14, 2020

Most recent

May 12, 2026

Reporting cadence

quarterly